Clinically stable treatment-experienced adults receiving tenofovir and didanosine.
METHODS
Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine.


RESULTS
Patients treated with TDF and ddI do not have a higher risk of early immunological or virological failure.


CONCLUSIONS
Treatment success and increase in CD4+ lymphocytes may depend, among other factors, on historical CD4+ nadir. These data agree with previous work and argue against preemptive switches for fear of side effects or immunological/virological failure away from a successful ddI-TDF combination in clinically stable drug-experienced patients.
Di Biagio
Antonio
A
Department of Infectious Diseases, University of Genova, Genova, Italy.
Beltrame
Andrea
A
Cenderello
Giovanni
G
Ferrea
Giuseppe
G
De Maria
Andrea
A
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006678:HIV / Q000254:growth & development*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D018119:Stavudine / Q000627:therapeutic use; D000068698:Tenofovir
D063065:Organophosphonates; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D000068698:Tenofovir; D018119:Stavudine; D000225:Adenine; D016049:Didanosine